Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Colleoni

Showing results (91-100 of 264) with videos related to

Pageof 27
Sort By:
Histopathology|June 15, 2013
The clinical relevance of micropapillary carcinoma of the breast: a case-control studyAndrea Vingiani, Patrick Maisonneuve, Patrizia Dell'orto, et al.
Cancer Chemotherapy and Pharmacology|July 20, 2007
Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expressionAndrea Rocca, Giuseppe Viale, Richard D Gelber, et al.
Breast (Edinburgh, Scotland)|February 21, 2012
Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumabSilvia Dellapasqua, Vincenzo Bagnardi, Francesco Bertolini, et al.
Breast (Edinburgh, Scotland)|December 1, 2009
Breast-conserving surgery in 201 very young patients (<35 years)Oreste Gentilini, Edoardo Botteri, Nicole Rotmensz, et al.
Breast Cancer Research and Treatment|August 6, 2013
Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal womenEdoardo Botteri, Elisabetta Munzone, Nicole Rotmensz, et al.
European Journal of Cancer (Oxford, England : 1990)|September 15, 2007
HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17Rosalba Torrisi, Nicole Rotmensz, Vincenzo Bagnardi, et al.
Anti-Cancer Drugs|February 3, 2009
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic featuresAlessandra Balduzzi, Emilia Montagna, Vincenzo Bagnardi, et al.
Breast (Edinburgh, Scotland)|March 15, 2011
Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancerSilvia Dellapasqua, Manuelita Mazza, Debora Rosa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to VMarco Colleoni, Zhuoxin Sun, Karen N Price, et al.
Breast (Edinburgh, Scotland)|August 16, 2006
Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancerRosalba Torrisi, Marco Colleoni, Paolo Veronesi, et al.
Pageof 27

Showing results (91-100 of 264) with videos related to

Sort By:
Pageof 27
Histopathology|June 15, 2013
The clinical relevance of micropapillary carcinoma of the breast: a case-control studyAndrea Vingiani, Patrick Maisonneuve, Patrizia Dell'orto, et al.
Cancer Chemotherapy and Pharmacology|July 20, 2007
Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expressionAndrea Rocca, Giuseppe Viale, Richard D Gelber, et al.
Breast (Edinburgh, Scotland)|February 21, 2012
Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumabSilvia Dellapasqua, Vincenzo Bagnardi, Francesco Bertolini, et al.
Breast (Edinburgh, Scotland)|December 1, 2009
Breast-conserving surgery in 201 very young patients (<35 years)Oreste Gentilini, Edoardo Botteri, Nicole Rotmensz, et al.
Breast Cancer Research and Treatment|August 6, 2013
Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal womenEdoardo Botteri, Elisabetta Munzone, Nicole Rotmensz, et al.
European Journal of Cancer (Oxford, England : 1990)|September 15, 2007
HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17Rosalba Torrisi, Nicole Rotmensz, Vincenzo Bagnardi, et al.
Anti-Cancer Drugs|February 3, 2009
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic featuresAlessandra Balduzzi, Emilia Montagna, Vincenzo Bagnardi, et al.
Breast (Edinburgh, Scotland)|March 15, 2011
Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancerSilvia Dellapasqua, Manuelita Mazza, Debora Rosa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to VMarco Colleoni, Zhuoxin Sun, Karen N Price, et al.
Breast (Edinburgh, Scotland)|August 16, 2006
Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancerRosalba Torrisi, Marco Colleoni, Paolo Veronesi, et al.
Pageof 27